Identification of novel serological tumor markers for human prostate cancer using integrative transcriptome and proteome analysis

Medical Oncology

Volumn 29, Issue 4, 2012, Pages 2877-2888

  Han, Zhao Dong ^a,g   Zhang, Yan Qiong ^b,c   He, Hui Chan ^a   Dai, Qi Shan ^a   Qin, Guo Qiang ^a   Chen, Jia Hong ^a   Cai, Chao ^a   Fu, Xin ^a   Bi, Xue Cheng ^d   Zhu, Jian Guo ^e   Liao, Dong Jiang ^f   Lu, Xin Peng ^f   Mo, Zi Yao ^f   Zhu, Yun Ping ^b   Zhong, Wei De ^a,f,g  

^a GUANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^b BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^c INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^d GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^e GUIZHOU PROVINCIAL PEOPLE'S HOSPITAL   (China)

^f GUANGZHOU MEDICAL UNIVERSITY   (China)

^g SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Inosine monophosphate dehydrogenase II; Integrative transcriptome and proteome analysis; Prostate cancer; Serological tumor marker

Indexed keywords

INOSINATE DEHYDROGENASE; INOSINE MONOPHOSPHATE DEHYDROGENASE II; PROTEOME; TRANSCRIPTOME; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER PATIENT; CANCER TISSUE; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE PRODUCT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MASS SPECTROMETRY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEOMICS; TRANSCRIPTOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION;

AGED; AGED, 80 AND OVER; CARBON-CARBON LIGASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMP DEHYDROGENASE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; PROTEOMICS; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL; TWO-DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS;

EID: 84867997051     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0149-9     Document Type: Article

References (34)

1. Bethesda, MD, http://seer.cancer.gov/csr/1975-2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011.
2. Kenfield SA, Stampfer MJ, Chan JM, Giovannucci E. Smoking and prostate cancer survival and recurrence. JAMA. 2011;305:2548-55.
3. Claverie JM. Computational methods for the identification of differential and coordinated gene expression. Hum Mol Genet. 1999;8:1821-32.
4. Wachi S, Yoneda K, Wu R. Interactome-transcriptome analysis reveals the high centrality of genes differentially expressed in lung cancer tissues. Bioinformatics. 2005;21:4205-8.
5. Collet B, Guitton N, Sakali S, et al. Differential analysis of glioblastoma multiforme proteome by a 2D-DIGE approach. Proteome Sci. 2011;9:16.
6. Klopfleisch R, Klose P, Weise C, et al. Proteome of metastatic canine mammary carcinomas: similarities to and differences from human breast cancer. J Proteome Res. 2010;9:6380-91.
7. Weeks ME. Urinary proteome profiling using 2D-DIGE and LC-MS/MS. Methods Mol Biol. 2010;658:293-309.
8. Corona G, De Lorenzo E, Elia C, et al. Differential proteomic analysis of hepatocellular carcinoma. Int J Oncol. 2010;36:93-9.
9. Muto T, Taniguchi H, Kushima R, et al. Global expression study in colorectal cancer on proteins with alkaline isoelectric point by two-dimensional difference gel electrophoresis. J Proteomics. 2011;74:858-73.
10. Nishimori T, Tomonaga T, Matsushita K, et al. Proteomic analysis of primary esophageal squamous cell carcinoma reveals downregulation of a cell adhesion protein, periplakin. Proteomics. 2006;6:1011-8.
11. Sinclair J, Metodieva G, Dafou D, Gayther SA, Timms JF. Profiling signatures of ovarian cancer tumour suppression using 2D-DIGE and 2D-LC-MS/MS with tandem mass tagging. J Proteomics. 2011;74:451-65.
12. Orenes-Piero E, Cortón M, González-Peramato P, et al. Searching urinary tumor markers for bladder cancer using a two-dimensional differential gel electrophoresis (2D-DIGE) approach. J Proteome Res. 2007;6:4440-8.
13. Pang J, Liu WP, Liu XP, et al. Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis. J Proteome Res. 2010;9:216-26.
14. Rong Y, Jin D, Hou C, et al. Proteomics analysis of serum protein profiling in pancreatic cancer patients by DIGE: up-regulation of mannose-binding lectin 2 and myosin light chain kinase 2. BMC Gastroenterol. 2010;10:68.
15. Dudoit S. Open source software for the analysis of microarray data. Biotechniques. 2003;Suppl:45-51.
16. Ihaka R, Gentleman R. R: a language for data analysis and graphics. J Comput Graph Stat. 1996;5:299-314.
17. Sun W, Xing B, Sun Y, et al. Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresis: novel protein markers in hepatocellular carcinoma tissues. Mol Cell Proteomics. 2007;6:1798-1808
18. Ma Y, Peng J, Huang L, et al. Searching for serum tumor markers for colorectal cancer using a 2-D DIGE approach. Electrophoresis. 2009;30:2591-2599
19. Stadler SC, Polanetz R, Maier EM, et al. Newborn screening for 3-methylcrotonyl-CoA carboxylase deficiency: population heterogeneity of MCCA and MCCB mutations and impact on risk assessment. Hum Mutat. 2006;27:748-59.
20. Takemoto K, Miyata S, Takamura H, Katayama T, Tohyama M. Mitochondrial TRAP1 regulates the unfolded protein response in the endoplasmic reticulum. Neurochem Int. 2011;58:880-7.
21. Liu D, Hu J, Agorreta J, et al. Tumor necrosis factor receptor-associated protein 1(TRAP1) regulates genes involved in cell cycle and metastases. Cancer Lett. 2010;296:194-205.
22. Leav I, Plescia J, Goel HL, et al. Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer. Am J Pathol. 2010;176:393-401.
23. Nguyen MC, Tu GH, Koprivnikar KE, Gonzalez-Edick M, Jooss KU, Harding TC. Antibody responses to galectin-8, TARP and TRAP1 in prostate cancer patients treated with a GM-CSF-secreting cellular immunotherapy. Cancer Immunol Immunother. 2010;59:1313-23.
24. Barnes BJ, Eakin AE, Izydore RA, Hall IH. Implications of selective type II IMP dehydrogenase (IMPDH) inhibition by the 6-ethoxycarbonyl-3, 3-disubstituted-1, 5-diazabicyclo[3.1.0]hexane-2, 4-diones on tumor cell death. Biochem Pharmacol. 2001;62:91-100.
25. Guidicelli G, Chaigne-Delalande B, Dilhuydy MS, et al. The necrotic signal induced by mycophenolic acid overcomes apoptosis-resistance in tumor cells. PLoS One. 2009;4:e5493.
26. Chong CR, Qian DZ, Pan F, et al. Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target. J Med Chem. 2006;49:2677-80.
27. Moosavi MA, Yazdanparast R, Sanati MH, Nejad AS. 3-Hydrogenkwadaphnin targets inosine 5′-monophosphate dehydrogenase and triggers post-G1 arrest apoptosis in human leukemia cell lines. Int J Biochem Cell Biol. 2005;37:2366-79.
28. He Y, Mou Z, Li W, et al. Identification of IMPDH2 as a tumor-associated antigen in colorectal cancer using immunoproteomics analysis. Int J Colorectal Dis. 2009;24:1271-9.
29. Fellenberg J, Bernd L, Delling G, Witte D, Zahlten-Hinguranage A. Prognostic significance of drug-regulated genes in high-grade osteosarcoma. Mod Pathol. 2007;20:1085-94.
30. Fellenberg J, Kunz P, Sfhr H, Depeweg D. Overexpression of inosine 5′-monophosphate dehydrogenase type II mediates chemoresistance to human osteosarcoma cells. PLoS One. 2010;5:e12179.
31. Collins CD, Purohit S, Podolsky RH, et al. The application of genomic and proteomic technologies in predictive, preventive and personalized medicine. Vascul Pharmacol. 2006;45:258-67.
32. Chiou SH, Wu CY. Clinical proteomics: current status, challenges, and future perspectives. Kaohsiung J Med Sci. 2011;27:1-14.
33. Ma Y, Peng J, Huang L, Liu W, Zhang P, Qin H. Searching for serum tumor markers for colorectal cancer using a 2-D DIGE approach. Electrophoresis. 2009;30:2591-9.
34. Varambally S, Yu J, Laxman B, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell. 2005;8:393-406.